Neural Cells Expressing Adenovirus E4ORF1 for Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no evidence to suggest that the adenovirus E4 region, particularly the E4ORF1 sequence, has beneficial effects on neuronal or glial cells, limiting its application in therapeutic contexts such as neuronal and glial regeneration and repair.
Innovation Solution
Expression of adenovirus E4ORF1 sequences in neural cells leads to increased proliferation rates and enhanced axon length and branching, allowing for the development of engineered neural cells that maintain their phenotypic characteristics, which can be used in therapeutic applications for neuronal and glial regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adenovirus E4ORF1 sequence is expressed in neural cells, then proliferation rate and axon development are improved, but risk of de-differentiation or transformation increases
Solution Approach 1:
The patent applies parameter changes by modifying the expression level and duration of E4ORF1 through controlled transduction protocols. By adjusting viral multiplicity of infection (MOI), transduction time, and expression control mechanisms, the patent optimizes proliferation enhancement while maintaining cellular identity stability, resolving the contradiction between productivity improvement and reliability preservation.
2Length of moving object
If adenovirus E4ORF1 sequence is expressed in neural cells, then axon length and branching are improved, but cellular transformation risk increases
Solution Approach 1:
The patent controls the expression parameters of E4ORF1 to achieve desired axon morphological changes without triggering transformation. By optimizing transduction conditions and expression levels, the patent enables axon length enhancement while maintaining cellular identity, resolving the contradiction between structural improvement and reliability preservation.
3Adaptability or versatility
If adenovirus E4ORF1 sequence is introduced to enhance neural cell proliferation, then therapeutic application potential is improved, but safety concerns increase
Solution Approach 1:
The patent converts the potential harmful effect of E4ORF1 expression (transformation risk) into a beneficial outcome by carefully controlling expression parameters. The same gene that could cause transformation is expressed at optimized levels to promote proliferation and axon development, transforming a potential harm into a therapeutic benefit while monitoring for adverse effects.
Solution Approach 2:
The patent resolves the safety concern by changing expression parameters including viral titer, transduction time, and expression control mechanisms. These parameter adjustments ensure that E4ORF1 expression achieves therapeutic effects (enhanced proliferation and axon development) while remaining below transformation thresholds, thus improving therapeutic potential without proportionally increasing harm.
Data Source
AI summary
In certain aspects the present invention provides engineered neural cells, neural stem cells, or neural progenitor cells that contain a nucleotide sequence that encodes an adenovirus E40RF1 polypeptide and/or that contain an adenovirus E40RF1 polypeptide. The present invention also provides methods of making and using such engineered cells and compositions comprising such engineered cells.